79544-27-7Relevant articles and documents
Preparation method of 2,6-dibromoaniline
-
Paragraph 0018-0020; 0026-0028, (2020/08/27)
The invention discloses a preparation method of 2,6-dibromoaniline. According to the method, 2,6-difluorobenzonitrile is used as an initial raw material, and the 2,6-dibromoaniline is synthesized through six steps of reactions including ammonolysis, diazotization bromination, re-ammonolysis, re-diazotization bromination, amidation and Hofmann degradation. The 2,6-dibromoaniline obtained in the process is a brown solid, and the purity of the 2,6-dibromoaniline is 98% or above.
Process for synthesizing 2-cyanogroup 3-fluorophenylboronic acid
-
Paragraph 0030, (2017/08/29)
The invention relates to a process for synthesizing 2-cyanogroup 3-fluorophenylboronic acid. According to the method, 3-bromofluorobenzene is used as a raw material, and takes a reaction with LDA and dimethylformamide in a tetrahydrofuran solvent to obtain 2-fluorine 6-bromobenzaldehyde; then, the 2-fluorine 6-bromobenzaldehyde and hydroxylamine hydrochloride take a reaction at 100 DEG C to obtain 2-fluorine 6-bromoxynil; finally, triisopropyl borate is added into the intermediate; n-butyllithium is dropwise added at -70 DEG C; reduced pressure distillation is performed to obtain 2-fluorine 6-bromophenylboronic acid. The process provided by the invention has the advantages that the operation is simple and convenient; the raw material can be easily obtained; the yield is high.
IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
-
Page 58, (2010/02/04)
A class of 8-fluoro-3-phenylimidazo[1,2-a]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group, or by a pyrrolidinonyl group, which is directly attached or bridged by an oxygen atom or by a -NH- or -OCH2- linkage, being selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.